Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Impact of the "Kid'EM App" Digital Guidance Tool for Setting Rehabilitation Goals by the Rehabilitation Professional for Children with Chronic Conditions Impacting Physical Health (READ'APP'T)

NCT06475950 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-03-01
Last updated
2025-02-05

Condition(s) studied

Children with Chronic Illnesses Affecting Physical Health

Investigational drug(s) / intervention(s)

Kid'EM app" experimental groupKid'EM app control group

Kid'EM app" experimental group: In the "Kid'EM app" experimental group arm, only the application used differs. Visits are organized in the same way as in the controle app arm. Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit Children are included in the study by the investigator, formalized by signing a consent form. Parents fill in questionnaires Visit 2 (when 1st objective is set): Telephone interview to assess performance and satisfaction levels after the first goal has been set. Visit 3 (when setting the 2nd goal): Telephone interview to assess performance and satisfaction levels after the second goal has been set. Visit 4 (week 14 - end of study): Physical visit The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input. Visit 4 bis: Telephone interview to assess performance and satisfaction levels after the work on the first two objectives. Visit 5 (focus group, optional post-study visit)

Kid'EM app control group: Use of control application without guidance for goal setting Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit Children are included in the study by the investigator, formalized by signing a consent form. Parents fill in questionnaires Visit 2 (when 1st objective is set): Telephone interview to assess performance and satisfaction levels after the first goal has been set. Visit 3 (when setting the 2nd goal): Telephone interview to assess performance and satisfaction levels after the second goal has been set. Visit 4 (week 14 - end of study): Physical visit The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input. Visit 4 bis: Telephone interview to assess performance and satisfaction levels after the work on the first two objectives. Visit 5 (focus group, optional post-study visit)

Study summary

On an individual level, the first expected benefit for the child using the "Kid'EM app" would be an improvement in the quality of his or her rehabilitation goals, which would be more Specific, Measurable, Activity-related, Realistic and Time-defined (SMART). A second expected benefit for the child, thanks to the work carried out in rehabilitation sessions on objectives adapted to his or her needs and day-to-day life, encouraging commitment and motivation, would be to improve the effectiveness of the care offered to him or her, thereby enhancing autonomy and physical health. For parents, taking part in goal-setting, by contributing their knowledge of their child and his or her daily life, would increase their involvement in their child's care and improve their satisfaction with the care offered. By setting SMART functional goals and facilitating communication between therapist, child and family, we expect to see a more child- and family-centred approach to care.

On a collective level, the "Kid'EM app" proposal would, as recommended by the WHO, improve professional rehabilitation practices and facilitate convergence towards good clinical practices for professionals (physiotherapists, occupational therapists, PRMs, etc.), thereby increasing the efficiency of the child rehabilitation care system.

If its value is demonstrated, the Kid'EM app could be adapted for children with other chronic illnesses requiring non-motor rehabilitation follow-up. The digitization of this goal-setting tool means that this low-cost practice could be widely disseminated.

Eligibility

Sex
ALL
Min age
1 Year
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Children with chronic illnesses affecting their physical health (e.g. Cerebral Palsy, Neuromuscular Disease, Brachial Plexus Paralysis, etc.). * Children receiving rehabilitation care to promote autonomy and physical health. * Child with at least one rehabilitation session/week with the same professional for a period of 3 months * Children aged 5 to 17 wishing to participate in the study * Parental consent for study participation and signature of consent form Exclusion Criteria: * Children without chronic illnesses that do not affect their physical health * Children unable to express their views and priorities * Children unable to collaborate with the rehabilitation professional when using the Kid'EM app * Children already familiar with the "Kid'EM app" product * Children whose parents are minors or unable to give informed consent

Primary outcome measure(s)

  • Quality of the first two objectives set for each child during the 12-week 'Kid'EM app' or 'app control' period — Up to 3 weeks
    Quality, adequate or not (binary criterion, measured with the SMART goal evaluation method: SMART GEM), of the first two goals set for each child during the 12-week period of use of the "Kid'EM app" or "control app".
  • Quality of the first two objectives set for each child during the 12-week 'Kid'EM app' or 'app control' period — From week 14 to week 16
    Quality, adequate or not (binary criterion, measured with the SMART goal evaluation method: SMART GEM), of the first two goals set for each child during the 12-week period of use of the "Kid'EM app" or "control app".

Trial sites (36)

FacilityCityRegionStatus
Ildys Ty Yann Angers France
Les Capucins Angers Angers France
IEM Galaxie Argeles France
SESSAD 93 - Aulnay Aulnay-sous-Bois France
SESSAD APF Basse Goulaine Basse-Goulaine France
SMR Concarneau Concarneau France
Dispositif sensoriel et moteur Clos Chauveau - DIJON Dijon France
Sessad APF France Handicap du Finistère Gouesnou France
CAMSP APF Grenoble Grenoble France
Cabinet de Kinésithérapie - Elodie CREACH Landerneau France
SESSAD 93-Raincy Le Raincy France
Cabinet d'Ergothérapie - Maison des Korrigans Lesneven France
SESSAD A Denn Askell - KERPAPE Lorient France
CAMSP Nelson Mandela Lyon France
CAPEDIA Lyon France
CMCR Les Massues Lyon France
CMRP Romans Ferrari - Service Brulologie Miribel France
CMRP Romans Ferrari - Service Neurologie Miribel France
IEM La Marrière Nantes France
CHU Carémeau Nîmes France
Cabinet Jaures Kiné Nîmes France
Cabinet Sophie CHAPELLIER Nîmes France
IEM La Cigale Nîmes France
SESSAD La Cigale Nîmes France
IEM Ar Menn Ploemeur France
Centre Paul DOTTIN Ramonville-Saint-Agne France
SESSAD Henri Matisse Rennes France
SESSAD Romans Romans-sur-Isère France
SMR pédiatrique ILDYS Roscoff France
SESSAD Saint Etienne Saint-Etienne France
CHU Saint Etienne - MPR Pédiatrique Saint-Etienne France
CMPR Côte d'Amour Saint-Nazaire France
Centre de l'Arche Saint-Saturnin France
UGECAM Strasbourg Strasbourg France
SMR Vannes - Centre hospitalier bretagne atlantique Vannes France
Sessad Apf Voiron Voiron France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06475950 on ClinicalTrials.gov ↗ ← All trials in France